Header Logo

Connection

ZHONGXING LIAO to Erlotinib Hydrochloride

Back to Details
This is a "connection" page, showing publications ZHONGXING LIAO has written about Erlotinib Hydrochloride.
ZHONGXING LIAO
Connection Strength
0.024
Erlotinib Hydrochloride
  1. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.